自2020年新冠肺炎疫情突发以来,全球生物安全风险愈加严峻,重大的新发突发传染病预防和控制是全球共同面对的重大问题,生物安全是国家生存发展的基本前提。发展生物医药产业能有效防范和应对危险生物因子及相关威胁,为人民生命健康构筑坚强屏障,维护国家安全和经济可持续发展。作为全球医药行业百强之首,国药集团充分发挥全产业链系统优势,全力推进科技创新,是全球唯一在“可诊、可治、可防”三个领域独立自主研发4款新冠肺炎诊断试剂、4款新冠肺炎治疗药物,在三条技术路线上成功研发4款新冠肺炎疫苗的企业,成为维护国家生物安全的战略科技力量。国药集团实施创新工程项目建设管理创新,实现了国内高等级生物安全疫苗生产车间“零”的突破,创造了全球医药类车间工程建设领域的奇迹,填补了我国人用疫苗高等级生物安全生产车间硬件标准和管理体系空白,建立形成国家疫苗战略应急储备体系,为快速有效应对新发突发公共卫生事件和重大传染病、打赢未来可能面临的“生物战”、维护国家战略安全奠定了坚实基础。国药集团新冠疫苗在119个国家、地区及国际组织获批注册上市或紧急使用,国内外生产供应35亿剂次,为服务国家政治、经济和外交大局,助力全球抗疫展示了中国科技和中国力量。
<<Since the sudden outbreak of the COVID-19 in 2020,the global biosecurity risk has become increasingly severe. The prevention and control of major emerging infectious diseases is a major problem faced by the world. Biosecurity is the basic prerequisite for the survival and development of a country. The development of the biopharmaceutical industry can effectively prevent and respond to dangerous biological factors and related threats,build a strong barrier for people’s lives and health,and maintain national security and sustainable economic development. As the top 100 in the global pharmaceutical industry,Sinopharm Group fully utilizes the advantages of the whole industry chain system and fully promotes scientific and technological innovation. 4 COVID-19 treatment drugs,companies that have successfully developed 4 COVID-19 vaccines on three technical routes have become a strategic scientific and technological force for maintaining national biosecurity. Sinopharm Group implemented innovative engineering project construction management innovation,achieved a breakthrough in domestic high-level biosafety vaccine production workshops,created a miracle in the field of global pharmaceutical workshop engineering construction,and filled China high-level biosafety production workshops for human vaccines The hardware standards and management system are blank,and a national vaccine strategic emergency reserve system has been established,which has laid a solid foundation for quickly and effectively responding to new public health emergencies and major infectious diseases,winning the “biological warfare” that may be faced in the future,and maintaining national strategic security. Sinopharm’s COVID-19 vaccine has been approved for registration or emergency use in 119 countries,regions and international organizations,and 3.5 billion doses have been produced and supplied at home and abroad,demonstrating China’s technology and strength to serve the overall political,economic and diplomatic situation of the country and help the global fight against the epidemic.
<<